13 results about "Desmosome" patented technology

The present invention includes a method of treating a subject having relapsing-remitting multiple sclerosis (RRMS) that is undergoing relapse, comprising: determining a level of expression for two or more biomarkers selected from urokinase plasminogen activator (uPA), kallikrein-8 (hK8), kallikrein-11 (hK11), or desmoglein-3 (DSG3) in a biological sample of a subject when compared to the same type of sample from a subject or a population of subjects that do not have RRMS; diagnosing that the subject in undergoing relapse if the level of expression of the two or more biomarkers has decreased in the subject; and administering a therapeutically effective amount of treatment for RRMS to the subject.

The disclosure provides methods of diagnosing, prognosing and stratifying cancers in a patient, comprising detecting elevated expression of desmoglein-2 (DSG-2) in a sample of the cancer and referencing that level to historic data to determine treatment regimen, stage, and prognosis of a patient.

The present invention provides a method and a pharmaceutical composition for treatment of skin diseases associated with accelerated comeodesmosomes degradation and / or weaker cell-cell adhesion, such as a peeling skin syndrome, Netherton syndrome, and atopic dermatitis.

The invention relates to the technical field of biology, in particular to desmosome-XVII type collagen fusion protein as well as a preparation method and application thereof. The invention provides a recombinant XVII type collagen fusion protein which comprises at least one XVII type collagen functional domain fragment and at least one functional domain fragment of desmosome core glycoprotein, the recombinant human X VII type collagen fusion protein provided by the invention has better cell adhesion activity and cell proliferation promoting activity. The recombinant human XVII type collagen fusion desmosis protein can significantly improve the adhesion between cells in a cell culture environment, and compared with commercial human XVII type collagen, the recombinant human XVII type collagen fusion desmosis protein can improve the effect by several times or more. In the aspect of promoting cell proliferation, the cell division cycle can be effectively shortened, so that the number of cells is rapidly increased within the same time, and the XVII type collagen is remarkably superior to commercial human XVII type collagen, and has wider application potential in the fields of skin care products, cosmetics, medicines, biomedical materials and the like.

The present invention relates to the use of a polypeptide or its antibody binding fragment that can form an antigen-antibody complex in contact with a biological sample obtained from the patient in the preparation of a vascular endothelial cell damage detection reagent or kit; wherein the polypeptide or its antibody binding fragment includes at least two selected from the following groups: alpha enolase protein (ENO1), talin 1 (TLN1), filament protein-A (FLNA), desmosome nexin (AHNAK), desmoglein-1 (DSG1), myosin light chain 1 (MYL1), heat shock protein 90β (HSP90AB1), cytoskeleton-associated protein 4 (CKAP4), membrane protrusion protein (MSN). The vascular endothelial cell autoantibodies of the present application can be used to diagnose vascular endothelial cell damage by simply detecting the titer in serum, and have very great clinical application value.

A method for diagnosing facioscapulohumeral muscular dystrophy (FSHD) using one or more biomarkers is provided. More particularly, provided is a method for diagnosing FSHD in a subject, the method comprising detecting the presence of a biomarker or change in level of a biomarker in a biological sample from the subject, wherein the biomarker is wherein the biomarker is mannose binding lectin 2 (MBL2), junction plakoglobin (JUP), desmoplakin (DSP), tetranectin (CLEC3B), complement component 7 (C7), complement component 9 (C9), tenascin C (TNG), lumican (LUM), phosphatidylinositol-glycan-specific phospholipase D (GPLD1 ), complement component 4 binding protein, beta chain (C4BPB), carnosine dipeptidase (CNDP1), or immunoglobulin kappa variable 2-30 (IGKV2-30), or a combination of any two or more of MBL2, JUP, DSP, CLEC3B, C7, C9, TNG, LUM, GPLD1, C4BPB, CNDP1, or IGKV2-30. In some aspects, when the change in level of the biomarker is an increase in the level of MBL2, JUP, DSP, CLEC3B, C7, C9, TNG, and / or LUM, or a combination of any thereof, the subject is diagnosed as having FSHD. In some aspects, when the change in level of the biomarker is a decrease in the level of GPLD1, C4BPB, CNDP1, and / or IGKV2-30, or a combination of any thereof, the subject is diagnosed as having FSHD. Also provided is a method for determining efficacy of a therapeutic treatment for FSHD in a subject, the method comprising measuring the level of a biomarker in a biological sample from the subject before and after the treatment, and determining that the treatment is effective in treating FSHD if the level of the biomarker is decreased or increased relative to a reference level or to the level of the biomarker in the sample from the subject before treatment, wherein when the biomarker is mannose binding lectin 2 (MBL2), junction plakoglobin (JUP), desmoplakin (DSP), tetranectin (CLEC3B), complement component 7 (C7), complement component 9 (C9), tenascin C (TNG), or lumican (LUM), or a combination of any two or more of MBL2, JUP, DSP, CLEC3B, C7, C9, TNG, or LUM, the treatment is effective when the level of the biomarker decreases, or wherein when the biomarker is phosphatidylinositol-glycan-specific phospholipase D (GPLD1), complement component 4 binding protein, beta chain (C4BPB), carnosine dipeptidase (CNDP1), or immunoglobulin kappa variable 2-30 (IGKV2-30), or a combination of any two or more of GPLD1, C4BPB, CNDP1, or IGKV2-30, the treatment is effective when the level of the biomarker increases. In various aspects, the method further comprises treating the subject diagnosed with FSHD.

The invention belongs to the field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating post-infection irritable bowel syndrome as well as a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 10 to 15 parts of rhizoma atractylodis macrocephalae, 10 to 20 parts of radix paeoniae alba, 3 to 7 parts of pericarpium citri reticulatae, 5 to 15 parts of radix saposhnikoviae, 10 to 20 parts of folium microcotis, 10 to 20 parts of plumeria rubra, 5 to 15 parts of kapok, 25 to 35 parts of rhizoma smilacis glabrae and 5 to 15 parts of flos albiziae. Animal experiments show that the traditional Chinese medicine composition can effectively improve diarrhea phenotypes and depressive symptoms of rats with PI-IBS liver depression and spleen deficiency syndromes, relieve high sensitivity of viscera, recover a tight junction structure and a cell desmosome structure of colon, up-regulate cell TJ protein expression, recover Th1 / Th2 immune imbalance of blood, reduce the level of proinflammatory factors (TNF-alpha) in colon tissue, and improve the immunity of the rats. And the levels of LPS, DAO and D-LA in serum are up-regulated. Therefore, the traditional Chinese medicine composition disclosed by the invention can be used for effectively treating the liver depression and spleen deficiency syndrome of the irritable bowel syndrome after infection.

The present invention relates to the use of a polypeptide or its antibody binding fragment that can form an antigen-antibody complex in contact with a biological sample obtained from the patient in the preparation of a vascular endothelial cell damage detection reagent or kit; wherein the polypeptide or its antibody binding fragment includes at least two selected from the following groups: alpha enolase protein (ENO1), talin 1 (TLN1), filament protein-A (FLNA), desmosome nexin (AHNAK), desmoglein-1 (DSG1), myosin light chain 1 (MYL1), heat shock protein 90β (HSP90AB1), cytoskeleton-associated protein 4 (CKAP4), membrane protrusion protein (MSN). The vascular endothelial cell autoantibodies of the present application can be used to diagnose vascular endothelial cell damage by simply detecting the titer in serum, and have very great clinical application value.

The invention relates to application of a corn feed containing human lysozyme, the corn feed is used for preparing products for preventing and / or treating animal intestinal diseases, and the amino acid sequence of the human lysozyme is shown as SEQ ID NO.1. The plant corn feed containing the human lysozyme is found for the first time, and can improve the intestinal barrier structure, the mitochondrial function and the immune function of animals suffering from intestinal diseases; the method has the advantages of prolonging the length of the intestinal tract of the animal with the intestinal disease, improving the microvillus state of the intestinal tract of the animal with the intestinal disease to enable the intestinal tract to be regular, improving the desmosome connection state of the intestinal tract of the animal with the intestinal disease to enable the intestinal tract of the animal with the intestinal disease to be orderly and clearly arranged, improving the SOD activity of the intestinal tract of the animal with the intestinal disease and the like.

The present application relates to the use of a polypeptide or antibody binding fragment thereof capable of forming an antigen-antibody complex with a biological sample obtained from the patient in the preparation of a reagent or kit for detecting vascular endothelial cell damage; wherein the polypeptide or antibody binding fragment thereof comprises at least two selected from the following group: alpha enolase protein (ENO1), ankle protein 1 (TLN1), filamin-A (FLNA), desmosomal linker protein (AHNAK), desmosomal core glycoprotein-1 (DSG1), myosin light chain 1 (MYL1), heat shock protein 90 beta (HSP90AB1), cytoskeleton-associated protein 4 (CKAP4), membrane spike protein (MSN). The vascular endothelial cell autoantibody of the present application can be used to diagnose vascular endothelial cell damage by simply detecting the titer in serum, which has very great clinical application value.

The invention belongs to the technical field of daily-use chemistry, and particularly relates to a keratin regulating composition containing mandelic acid and having skin smoothing and brightening effects and application of the keratin regulating composition. The composition provided by the invention comprises mandelic acid, lactobionic acid, hydroxyethyl piperazine ethanesulfonic acid, lactobacillus / soybean milk fermentation product filtrate and lactobacillus fermentation lysate. According to the application, mandelic acid, lactobionic acid, hydroxyethyl piperazine ethanesulfonic acid, lactobacillus / soybean milk fermentation product filtrate and lactobacillus fermentation lysate are compounded, so that the activity of KLK family proteases, especially kallikrein 5 (KLK5), can be obviously promoted, the decomposition of desmosome between keratinocytes is promoted, epidermal cells lose cohesion and finally naturally fall off, and the effect of promoting the activity of KLK family proteases is achieved. The cutin exfoliation promoting effect is achieved, so that the problems of skin darkness, roughness, pore blockage, acne and the like are solved, the glossiness and fineness of the skin are improved, and healthy and bright skin is achieved.